CCL2

CCL2

CCL2 詳細

Molecule Name
C-C motif chemokine 2
分子の別称
CCL2,C-C motif chemokine 2,MCP-1,MCAF
Drug Development Progress
治験薬の数3
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
MCP1,HC11,Monocyte chemotactic protein 1,Monocyte chemoattractant protein 1,CCL2,C-C Motif Chemokine Ligand 2,Monocyte Chemotactic And Activating Factor,Monocyte Secretory Protein JE,Small Inducible Cytokine A2 (Monocyte Chemotactic Protein 1, Homologous To Mouse Sig-Je),Small Inducible Cytokine Subfamily A (Cys-Cys), Member 2,Monocyte Chemoattractant Protein-1,Chemokine (C-C Motif) Ligand 2,Small-Inducible Cytokine A2,SCYA2,MCP-1,MCAF,Monocyte Chemotactic Protein 1, Homologous To Mouse Sig-Je,C-C Motif Chemokine 2,HSMCR30,GDCF-2,SMC-CF,Chemokine CCL2,MGC9434
バックグランド
Chemokines are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. CCL2, a member of the CC subfamily, is characterized by two adjacent cysteine residues. CCL2 displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4. Elevated expression of the encoded protein is associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

CCL2 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
AFX-5931AFX-5931Phase 2 ClinicalAfecta Pharmaceuticals Inc
Eczema
詳細
MW-151MW01-9-034WH; MW-151; MW01-2-151SRMPhase 1 ClinicalUniversity Of Kentucky
Drug-Related Side Effects and Adverse Reactions; Poisoning
詳細
64CU-DOTA-ECL1iPhase 1 ClinicalWashington University School Of Medicine
Arteriosclerosis; Carotid Artery Diseases; Heart Diseases
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
PropagermaniumSK-818; SK-818CApprovedSanwa Kagaku Kenkyusho Co LtdSerocionJapanHepatitis BSanwa Kagaku Kenkyusho Co Ltd1994-01-01
Hepatitis B
詳細